Kezar Life Sciences, Inc. - KZR STOCK NEWS

Kezar Life Sciences, Inc. (Nasdaq: KZR) will host a virtual Investor and Analyst Day on November 15, 2021, at 4:30 p.m. ET. The event will highlight interim data from the MISSION study on KZR-616, a selective immunoproteasome inhibitor for lupus nephritis. Additionally, KZR-261, a novel anti-tumor agent, will be discussed, alongside the Phase 1 trial design. Presenters include CEO John Fowler and CMO Noreen Roth Henig. The presentation will be followed by a Q&A session. Register at event link.

Kezar Life Sciences (NASDAQ: KZR) announced the dosing of the first patient in the KZR-261-101 trial, evaluating KZR-261, a novel anti-tumor agent. This Phase 1 study aims to assess safety, tolerability, pharmacokinetics, and preliminary efficacy in patients with solid tumors. The trial consists of a dose escalation and expansion phase. KZR-261 is the first clinical candidate from Kezar's protein secretion platform, targeting the Sec61 translocon. The company anticipates that KZR-261's unique profile may offer significant potential in oncology.

Kezar Life Sciences (NASDAQ: KZR) has appointed Gitanjali Jain as Vice President of Investor Relations and External Affairs. Jain brings over 15 years of healthcare experience, previously advising biopharmaceutical companies at Solebury Trout. She will guide Kezar's investor relations and scientific communications. CEO John Fowler expressed enthusiasm about her addition, anticipating her expertise will enhance the company's efforts in developing therapies for immune-mediated and oncologic disorders, including KZR-616 and KZR-261.

Kezar Life Sciences (Nasdaq: KZR) has announced participation in two upcoming virtual investor conferences. The Wells Fargo Virtual Healthcare Conference is scheduled for September 9, 2021, at 4:00 PM ET, featuring CEO John Fowler and CMO Noreen Roth Henig. The H. C. Wainwright 23rd Annual Global Investment Conference will occur on September 13, 2021, at 7:00 AM ET, with John Fowler presenting. Webcasts can be accessed on the company’s website and will be archived for 90 days.

Kezar Life Sciences, Inc. (KZR) has completed enrollment in its Phase 2 PRESIDIO trial, evaluating KZR-616 for polymyositis (PM) and dermatomyositis (DM). The study, which involves 24 subjects, is a randomized, placebo-controlled trial designed to assess safety and efficacy over 32 weeks. Patients receive either KZR-616 or placebo, with top-line results expected in Q2 2022. KZR-616 has received Orphan Drug Designation from the FDA for PM and DM. This milestone is viewed as significant for advancing treatment options for these debilitating conditions.

Kezar Life Sciences, Inc. (KZR) reported its second quarter 2021 financial results, highlighting the completion of a Phase 1b study for KZR-616, which showed positive safety and efficacy in lupus nephritis patients. The company submitted an IND for KZR-261, aiming to initiate a Phase 1 trial for this anti-tumor agent. Q2 2021 net loss was $13 million, or $0.25 per share, compared to a loss of $9.5 million, or $0.22 per share, in Q2 2020. Cash reserves decreased from $140 million at year-end 2020 to $129 million, attributed to R&D expenses.

Kezar Life Sciences (Nasdaq: KZR) announced that Co-founder and Chief Scientific Officer, Christopher Kirk, will join the panel discussion on "Novel Targets for Autoimmune Diseases" at William Blair's Biotech Focus Conference on July 15, 2021, at 11:00 a.m. ET. The event will be webcast live, accessible through the Events & Presentations section of Kezar's website, with a replay available for 90 days post-conference. Kezar focuses on innovative treatments for autoimmune diseases and cancer, including KZR-616, currently in Phase 2 trials for lupus nephritis and other conditions.

Kezar Life Sciences (Nasdaq: KZR) has established a Clinical Advisory Committee to enhance clinical development strategies for its lead candidate, KZR-616, aimed at autoimmune diseases. This committee, comprising experts from various medical fields, will guide the company's therapeutic programs and patient-centric approaches. KZR-616 is a first-in-class selective immunoproteasome inhibitor currently undergoing Phase 2 trials for severe autoimmune conditions, demonstrating a favorable safety profile in earlier studies.

Kezar Life Sciences, Inc. (Nasdaq: KZR) announced results from the Phase 1b dose escalation of its MISSION study, focusing on KZR-616 for systemic lupus erythematosus (SLE). This first-in-class immunoproteasome inhibitor showed favorable safety and tolerability in 47 patients. The study observed significant improvement in disease activity scores, including reductions in anti-double-stranded DNA antibodies. Among patients with proliferative lupus nephritis, notable reductions in urine protein levels were recorded. The poster presented at EULAR highlights KZR-616's potential to transform treatment for SLE and lupus nephritis.